Kate applies training received as a Ph.D. in molecular biology, cell biology, and genetics to strategic, scientifically sound protection of life sciences, biotechnology, and pharmaceuticals inventions.
Her broad experience in a range of biochemistry, proteomic, cell culture, animal model, molecular biology, and genetic techniques provides her with an invaluable perspective on the complexities behind the development of cutting edge technologies.
Prior to joining Michael Best, Kate worked as a postdoctoral research fellow at the Medical College of Wisconsin Biotechnology and Bioengineering Center, where she studied the role of altered proteomic compositions of HDL particles in the development and progression of non-alcoholic fatty liver disease. She also evaluated the role of diet in chemoprevention through basic science and clinical trials.
Kate’s research experience also includes identifying a novel mutation in a gene that regulates cholesterol biosynthesis in a mouse model of cataracts and spontaneous persistent skin sounds. She subsequently worked to elucidate the role of cholesterol homeostasis in maintaining eye lens transparency and the integrity of skin barrier properties.